|
|
Article: Cerus and Baxter Report Positive Results in Trial of INTERCEPT Red Blood Cells; Companies Prepare for Phase III Clinical Trials.
- Article from:
- Business Wire
- Article date:
- October 17, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health & Medical Writers
SAN ANTONIO--(BW HealthWire)--Oct. 17, 2001
Cerus Corporation (Nasdaq:CERS) and Baxter Healthcare Corporation (NYSE:BAX) today announced preliminary results from the Phase Ic clinical trial of their INTERCEPT Red Blood Cell System, a pathogen inactivation system being developed to protect against transmission of infectious diseases through red blood cell transfusions. The results showed that INTERCEPT red blood cells were well tolerated and demonstrated comparable recovery and survival performance to red blood cells which had not been treated with the pathogen inactivation process. The data were presented by ...